These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

284 related items for PubMed ID: 9224570

  • 21. Methionine aminopeptidase‑2 is a pivotal regulator of vasculogenic mimicry.
    Shimizu S, Kawahara R, Simizu S.
    Oncol Rep; 2022 Feb; 47(2):. PubMed ID: 34913067
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. The anti-angiogenic agent fumagillin covalently modifies a conserved active-site histidine in the Escherichia coli methionine aminopeptidase.
    Lowther WT, McMillen DA, Orville AM, Matthews BW.
    Proc Natl Acad Sci U S A; 1998 Oct 13; 95(21):12153-7. PubMed ID: 9770455
    [Abstract] [Full Text] [Related]

  • 28. Microsporidian methionine aminopeptidase type 2.
    Weiss LM, Costa SF, Zhang H.
    J Eukaryot Microbiol; 2001 Oct 13; Suppl():88S-90S. PubMed ID: 11906093
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Antiparasitic activities of novel, orally available fumagillin analogs.
    Arico-Muendel C, Centrella PA, Contonio BD, Morgan BA, O'Donovan G, Paradise CL, Skinner SR, Sluboski B, Svendsen JL, White KF, Debnath A, Gut J, Wilson N, McKerrow JH, DeRisi JL, Rosenthal PJ, Chiang PK.
    Bioorg Med Chem Lett; 2009 Sep 01; 19(17):5128-31. PubMed ID: 19648008
    [Abstract] [Full Text] [Related]

  • 33. Methionine Aminopeptidase 2 as a Potential Therapeutic Target for Human Non-Small-Cell Lung Cancers.
    Shimizu H, Yamagishi S, Chiba H, Ghazizadeh M.
    Adv Clin Exp Med; 2016 Sep 01; 25(1):117-28. PubMed ID: 26935506
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Methionine aminopeptidase-2 as a selective target of myofibroblasts in pulmonary fibrosis.
    Kass D, Bridges RS, Borczuk A, Greenberg S.
    Am J Respir Cell Mol Biol; 2007 Aug 01; 37(2):193-201. PubMed ID: 17446530
    [Abstract] [Full Text] [Related]

  • 36. Small molecule inhibitors of methionine aminopeptidase type 2 (MetAP-2).
    Garrabrant T, Tuman RW, Ludovici D, Tominovich R, Simoneaux RL, Galemmo RA, Johnson DL.
    Angiogenesis; 2004 Aug 01; 7(2):91-6. PubMed ID: 15516829
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Treatment of cells with the angiogenic inhibitor fumagillin results in increased stability of eukaryotic initiation factor 2-associated glycoprotein, p67, and reduced phosphorylation of extracellular signal-regulated kinases.
    Datta B, Majumdar A, Datta R, Balusu R.
    Biochemistry; 2004 Nov 23; 43(46):14821-31. PubMed ID: 15544353
    [Abstract] [Full Text] [Related]

  • 39. Tumor suppression by a rationally designed reversible inhibitor of methionine aminopeptidase-2.
    Wang J, Sheppard GS, Lou P, Kawai M, BaMaung N, Erickson SA, Tucker-Garcia L, Park C, Bouska J, Wang YC, Frost D, Tapang P, Albert DH, Morgan SJ, Morowitz M, Shusterman S, Maris JM, Lesniewski R, Henkin J.
    Cancer Res; 2003 Nov 15; 63(22):7861-9. PubMed ID: 14633714
    [Abstract] [Full Text] [Related]

  • 40. Structure of the angiogenesis inhibitor ovalicin bound to its noncognate target, human Type 1 methionine aminopeptidase.
    Addlagatta A, Matthews BW.
    Protein Sci; 2006 Aug 15; 15(8):1842-8. PubMed ID: 16823043
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.